Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies?

C. Hewison (Paris, France)

Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Disease area: Respiratory infections

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Hewison (Paris, France). Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies?. International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The efficacy and safety of new combined medicinal product in the treatment of influenza: The results of a multicenter randomized comparative clinical trial
Source: Annual Congress 2013 –Viral infections: what is new?
Year: 2013


What could we learn from ongoing therapeutic trials?
Source: ERS Research Seminar
Year: 2015


Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Clinical trial landscape for M/XDR-TB: current evidence and future perspectives
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019


Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry
Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Year: 2017


Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


Negative clinical trials in sarcoidosis: failed therapies or flawed study design?
Source: Eur Respir J 2014; 44: 1123-1126
Year: 2014


Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine
Source: Virtual Congress 2021 – Cystic fibrosis
Year: 2021


Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Source: ERJ Open Res, 4 (4) 00084-2018; 10.1183/23120541.00084-2018
Year: 2018



Efficacy and safety of omalizumab in real-life practice in India
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012


Late Breaking Abstract - Knowledge, anxiety and use of hydroxychloroquine prophylaxis among healthcare students and professionals regarding COVID-19 pandemic in India: An observational cross-sectional study
Source: Virtual Congress 2020 – COVID-19 clinical studies
Year: 2020


Clinical case discussion: How clinical trials inform antibiotic stewardship
Source: ERS webinar 2022: Clinical case discussion: How clinical trials inform antibiotic stewardship
Year: 2022


New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
Source: Eur Respir Rev 2014; 23: 367-378
Year: 2014



Clinical trials during the COVID-19 pandemic: research design and lessons
Source: Eur Respir Monogr 2021; 94: 214-231
Year: 2021


Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability
Source: Eur Respir J, 51 (2) 1701531; 10.1183/13993003.01531-2017
Year: 2018



Clinical effectiveness of self-management of asthma in general practice: a randomized controlled trial
Source: Eur Respir J 2001; 18: Suppl. 33, 518s
Year: 2001